论文部分内容阅读
目的观察凯西莱预防抗结核药物所致肝细胞损害的疗效。方法对收治的肺结核病人予抗结核治疗的同时,辅以凯西莱或葡醛内酯治疗,统计肝功能异常例数及发生时间等。结果凯西莱组(300例)出现肝损害25例(8.3%),对照组(300例)葡醛内酯组出现肝损害100例(33.3%),两组比较差异有统计学意义(P<0.05)。且凯西莱组出现肝损害时间相对较晚,主要在治疗的第2~3个月,而葡醛内酯组主要在治疗的第1~2个月,且凯西莱组出现肝损害程度相对较轻。结论凯西莱预防抗结核药物所致肝细胞损害有确切疗效。
Objective To observe the curative effect of prevention of hepatocellular damage caused by anti-tuberculosis drugs in Kesilai. Methods Tuberculosis patients admitted to treat tuberculosis at the same time, supplemented by Kesilai or glucurolactone treatment, statistics of the number of liver dysfunction and the occurrence of time. Results Liver damage was found in 25 cases (8.3%) in Caseisila group (300 cases) and 100 cases (33.3%) in control group (300 cases). The difference between the two groups was statistically significant (P <0.05). And Cisilai group of liver damage occurred relatively late, mainly in the treatment of 2 to 3 months, while the glucurolactone group in the first 1 to 2 months of treatment, and Kesilai group of liver damage Relatively light. Conclusion Kesilai to prevent the anti-TB drug-induced liver cell damage has the exact effect.